TY - JOUR
T1 - A novel approach to cardiovascular health by optimizing risk management (ANCHOR)
T2 - Behavioural modification inprimary care effectively reduces global risk
AU - Cox, Jafna L.
AU - Vallis, T. Michael
AU - Pfammatter, Angela
AU - Szpilfogel, Claudine
AU - Carr, Brendan
AU - O'Neill, Blair J.
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2013/11
Y1 - 2013/11
N2 - Background: Primary care is well positioned to facilitate cardiovascular risk improvement and reduce future cardiovascular disease (CVD) burden. Methods: The efficacy of risk factor screening, behavioural counselling, and pharmacological treatment to lower CVD risk was assessed via a prospective pre- and postintervention health risk assessment, individualized intervention with behaviour modification, risk factor treatment, and linkage to community programs, with 1-year follow-up and final health risk assessment. Primary outcome was the proportion of subjects with moderate and high baseline Framingham Risk Score (FRS) reducing their risk by 10% and 25%, respectively; the secondary end point was the proportion dropping ≥ 1 risk category. Results: Patients were enrolled (N= 1509) from March 2006 through October 2008 and 72% completed the study. This analysis focuses on 563 subjects with moderate or high baseline FRS, and excluded 325 low-risk patients and 205 with established CVD or diabetes mellitus. Median age was 56 years, 57.7% were female. The primary outcome was achieved in 31.8% (N= 112; 95% confidence interval [CI], 26.9%-36.6%) of moderate risk FRS participants and 47.9% (N= 101; 95% CI, 41.2%-54.6%) of high-risk participants. The secondary outcome was achieved by 37.2% (N= 210; 95% CI, 33.2%-41.2%). Prevalence of metabolic syndrome fell from 79.2% (N= 446; 95% CI, 75.9%-82.6%) at entry to 52.8% (N= 303; 95% CI, 48.7%-56.9%) at study end. Significant improvements in all modifiable risk factors occurred through lifestyle modification. Conclusions: Global cardiovascular risk can be effectively decreased via lifestyle changes informed by readiness to change assessment and individualized counselling targeting specific behaviours. Trial registration: ClinicalTrials.gov number NCT01620996.
AB - Background: Primary care is well positioned to facilitate cardiovascular risk improvement and reduce future cardiovascular disease (CVD) burden. Methods: The efficacy of risk factor screening, behavioural counselling, and pharmacological treatment to lower CVD risk was assessed via a prospective pre- and postintervention health risk assessment, individualized intervention with behaviour modification, risk factor treatment, and linkage to community programs, with 1-year follow-up and final health risk assessment. Primary outcome was the proportion of subjects with moderate and high baseline Framingham Risk Score (FRS) reducing their risk by 10% and 25%, respectively; the secondary end point was the proportion dropping ≥ 1 risk category. Results: Patients were enrolled (N= 1509) from March 2006 through October 2008 and 72% completed the study. This analysis focuses on 563 subjects with moderate or high baseline FRS, and excluded 325 low-risk patients and 205 with established CVD or diabetes mellitus. Median age was 56 years, 57.7% were female. The primary outcome was achieved in 31.8% (N= 112; 95% confidence interval [CI], 26.9%-36.6%) of moderate risk FRS participants and 47.9% (N= 101; 95% CI, 41.2%-54.6%) of high-risk participants. The secondary outcome was achieved by 37.2% (N= 210; 95% CI, 33.2%-41.2%). Prevalence of metabolic syndrome fell from 79.2% (N= 446; 95% CI, 75.9%-82.6%) at entry to 52.8% (N= 303; 95% CI, 48.7%-56.9%) at study end. Significant improvements in all modifiable risk factors occurred through lifestyle modification. Conclusions: Global cardiovascular risk can be effectively decreased via lifestyle changes informed by readiness to change assessment and individualized counselling targeting specific behaviours. Trial registration: ClinicalTrials.gov number NCT01620996.
UR - http://www.scopus.com/inward/record.url?scp=84886949840&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886949840&partnerID=8YFLogxK
U2 - 10.1016/j.cjca.2013.03.007
DO - 10.1016/j.cjca.2013.03.007
M3 - Article
C2 - 23796526
AN - SCOPUS:84886949840
VL - 29
SP - 1400
EP - 1407
JO - Canadian Journal of Cardiology
JF - Canadian Journal of Cardiology
SN - 0828-282X
IS - 11
ER -